References
- Dressier D. Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;73:604
- Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry 1995;59:102–3
- BOTOX® [package insert]. Irvine, CA: Allergan Inc.; 2004. Available from http://www.allergan.com/site/products/consumers/prescribing_info.asp?id=botox&largeText [last accessed 19 January 2005]
- Dysport® [data sheet]. Auckland, NZ: Ipsen; 2003. Available from http://www.medsafe.govt.nz/profs/datasheet/d/dysportinj. htm [last accessed 19 January 2005]
- Poewe W Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo-controlled, dose ranging study using Dysport [German Dystonia Study Group]. J Neurol Neurosurg Psychiatry 1998;64:13–7
- Laubis-Herrmann U, Fries K, Topka H. Low-dose botulinum toxin a treatment of cervical dystonia – a double-blind, randomized pilot study. Eur Neurol 2002;47:214–21
- Odergren T Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6–12
- Hambleton P Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994;87:719
- Wohlfarth K, Goschel H, Frevert J, et al. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997;355:335–40
- Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol 1995;2:17–8
- Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A – Dysport and Botox – assuming a ratio of 4:1. Mov Disord 1997;12:1013–8
- Whurr R, Brookes G, Barnes C. Comparison of dosage effects between the American and the British botulinum toxin A product in the treatment of spasmodic dysphonia. Mov Disord 1995;10:56
- Nussgens Z, Roggenkamper P. Comparison of two botulinum toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997;235:197–9
- Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs Botox in primary palmar hyperhidrosis. Br J Dermatol 2003;149:1041–5
- Ranoux D, Gury C, Fondarai J, Mas JL, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459–62
- Hsiung GY, Das SK, Ranawaya R, et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288–93